Command Palette

Search for a command to run...

Preprint WatchModerateOctober 15th, 2026

X-chromosome methylation patterns in females with multiple sclerosis

Calnin, T.; Maltby, V. E.; Burnard, S. M.; Xavier, A.; Simpson-Yap, S.; van der Mei, I.; Broadley, S.; Taylor, B. V.; Butzkueven, H.; Ponsonby, A.-L.; Scott, R. J.; Jagodic, M.; Jokubaitis, V. G.; Lechner-Scott, J.; Lea, R. A.

X-chromosome CpGs are hypomethylated in females with multiple sclerosis, with 3,182 sites at FDR below 0.01 and a mean beta difference of -0.035, and exploratory cis-mQTL analysis identifies strong local genetic effects at a small subset of loci including WAS, IRAK1 and TLR7.

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

The preprint reports X-chromosome hypomethylation in females with multiple sclerosis across three datasets comprising 496 cases and 509 controls, with 65.4 percent of whole-blood hypomethylated CpGs replicating in CD4-positive T cells, and names TLR7 among loci with strong local genetic effects on methylation. It does not test TLR7 pharmacology or propose TLR7 as a drug target. Claidex records one TLR7 failure, enpatoran-tlr7-tlr8-dermatomyositis-polymyositis-phase2-futility, a Phase 2 in dermatomyositis and polymyositis stopped for futility, which sets the archetype driving this severity band. The relevance is narrow and worth stating plainly: a regulatory methylation signal at TLR7 in a different autoimmune disease is a reason to ask whether TLR7 expression was ever confirmed as elevated and functionally required in the enrolled population of the failed trial, not evidence that the target works.

Abstract excerpt

Multiple sclerosis (MS) is approximately three times more common in females than in males, but sex-linked epigenetic mechanisms remain incompletely understood. We tested whether X-chromosome DNA methylation differs in females with MS and whether associated sites preferentially map to genes normally subject to X-chromosome inactivation (XCI). An X-chromosome-focused epigenome-wide association study was performed in whole blood from three datasets comprising 496 females with MS and 509 female controls, with independent evaluation in isolated CD4+ T cells (80 cases, 76 controls). At FDR < 0.01, 3 182 X-chromosome CpGs were hypomethylated in MS (mean {Delta}{beta} = -0.035). Hypomethylated CpGs were strongly enriched in non-escape genes normally subject to XCI relative to escape genes (OR 6.77; p = 1.55x10-57) and mapped to immune and chromatin-related processes. Exploratory cis-mQTL analysis identified strong local genetic effects at a small subset of loci, including WAS, IRAK1 and TLR7. In CD4+ T cells, 2 080 of the 3,182 whole-blood hypomethylated CpGs (65.4%) were also significantly hypomethylated. These findings identify a reproducible X-chromosome hypomethylation signature in female MS and support direct investigation of inactive-X regulation, XCI escape and X-linked immune gene dosage.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.